The future of obesity treatment is polyagonist anorectic agents combined with metabolic enhancers (mitochondrial uncouplers, leptin analogs, etc.). The right combination of therapy would normalize energy homeostasis and remit obesity in all people.
People who struggle to feel sated suddenly don’t {with GLP1s}, effectively giving “someone the willpower of those lucky enough to have won the genetic lottery,” said Dr. Brierley.
Scarioni et al. show that neuropsychiatric symptoms in FTD are associated with subcortical pathology in the hippocampus, with hallucinations associated with a higher burden of TDP-43 pathology in the granular layer. bit.ly/3XWV3cHpic.twitter.com/mOrwzTJiUC
A new paper aims to improve understanding of the links between overweight or obesity and CVD, the key controversies in this area, and evidence relating to cardiometabolic outcomes with available weight management options.